ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -11 مورد

COVID-19 vaccines available in the United States[1-6]

COVID-19 vaccines available in the United States[1-6]
Name Platform Indicated ages Dose WITHOUT moderate to severe immunocompromising condition WITH moderate to severe immunocompromising condition
Moderna COVID-19 vaccine (2024-2025 Formula; based on KP.3 Omicron variant) mRNA 6 months through 4 years 25 mcg (0.25 mL) For individuals not previously vaccinated with any COVID-19 vaccine*:
  • Two vaccine doses 4 to 8 weeks apart
 For individuals not previously vaccinated with any COVID-19 vaccine*:
  • Three vaccine doses:
    • First two given 4 weeks apart
    • Third given at least 4 weeks after the second

For individuals who have received at least three mRNA vaccine doses (as above) but not with a 2024-2025 Formula vaccine dose:

  • Two 2024-2025 Formula vaccine doses approximately 6 months apart (minimum of 2 months apart)Δ
  • Additional 2024-2025 Formula vaccine doses, given at least 2 months after the last, are an option
5 through 11 years 25 mcg dose (0.25 mL) For all immunocompetent individuals in these age groups:
  • Single 2024-2025 Formula vaccine doseΔ
12 to 64 years 50 mcg (0.5 mL)
65 years and older 50 mcg (0.5 mL) For all immunocompetent individuals in this age group:
  • Two 2024-2025 Formula vaccine doses approximately 6 months apart (minimum of 2 months apart)Δ
Pfizer/BioNTech COVID-19 vaccine (2024-2025 Formula; based on KP.3 Omicron variant) mRNA 6 months through 4 years◊ 3 mcg (0.3 mL yellow-capped vial) For individuals not previously vaccinated with any COVID-19 vaccine*:
  • Three vaccine doses:
    • First two given 3 to 8 weeks apart
    • Third given at least 8 weeks after the second
 For individuals not previously vaccinated with any COVID-19 vaccine*:
  • Three vaccine doses:
    • First two given 3 weeks apart
    • Third given at least 4 weeks (for ages 5 years and older) or 8 weeks (for ages 6 months through 4 years) after the second

For individuals who have received at least three mRNA vaccine doses (as above) but not with a 2024-2025 Formula vaccine dose:

  • Two 2024-2025 Formula vaccine doses approximately 6 months apart (minimum of 2 months apart)Δ
  • Additional vaccine doses, given at least 2 months after the last, are an option
5 through 11 years 10 mcg (0.3 mL blue-capped vial) For all immunocompetent individuals in these age groups:
  • Single 2024-2025 Formula vaccine doseΔ
12 to 64 years 30 mcg (0.3 mL)
65 years and older 30 mcg (0.3 mL) For all immunocompetent individuals in this age group:
  • Two 2024-2025 Formula vaccine doses approximately 6 months apart (minimum of 2 months apart)Δ
Novavax COVID-19 vaccine (2024-2025 Formula; based on JN.1 Omicron variant) Recombinant protein, adjuvanted 12 to 64 years 5 mcg spike protein/50 mcg adjuvant doses (0.5 mL) For individuals not previously vaccinated with any COVID-19 vaccine:
  • Two vaccine doses 3 to 8 weeks apart

For individuals who have received at least one prior COVID-19 vaccine dose (other than a 2024-2025 Formula vaccine):

  • Single 2024-2025 Formula vaccine dose at least 8 weeks after last dose§
 For individuals not previously vaccinated with any COVID-19 vaccine*:
  • Two vaccine doses given three weeks apart

For individuals who have received at least two Novavax vaccine doses (as above) but not with a 2024-2025 Formula vaccine dose:

  • Two 2024-2025 Formula vaccine doses approximately 6 months apart (minimum of 2 months apart)Δ
  • Additional vaccine doses, given at least 2 months after the last, are an option
65 years and older 5 mcg spike protein/50 mcg adjuvant doses (0.5 mL) For individuals not previously vaccinated with any COVID-19 vaccine:
  • Two vaccine doses 3 to 8 weeks apart

For individuals who have received at least one prior COVID-19 vaccine dose (but not a 2024-2025 Formula vaccine):

  • Two 2024-2025 Formula vaccine doses approximately 6 months apart (minimum of 2 months apart)Δ
We recommend vaccination with one of these vaccines for eligible individuals.

CDC: Centers for Disease Control and Prevention; COVID-19: coronavirus disease 2019.

* For individuals younger than five years of age and individuals with moderately to severely immunocompromising conditions who have already received previous vaccine doses, recommendations on updated vaccine doses depend on the number of prior vaccines received. If they have received at least three mRNA vaccine doses, the updated vaccine should be given at least eight weeks after the most recent dose. Refer to other UpToDate content for details.

¶ Although the FDA authorized intervals for the second doses of the Moderna, Novavax, and Pfizer COVID-19 vaccines are four, three, and three weeks after the first dose, respectively, the CDC suggests an interval up to eight weeks. Extending the interval to eight weeks between vaccine doses may be preferable for those (especially males aged 12 to 39 years) who have no major comorbidities and do not need to maximize protection within a shorter period of time; longer intervals may be associated with a lower risk of myocarditis and slightly improved effectiveness.[5]

Δ If the patient was previously vaccinated with other formulations, give the first 2024-2025 Formula vaccine dose at least 8 weeks after the last vaccine.

◊ Children who turn five years of age during the series should receive all three doses with the formulation and dose recommended for children six months through four years.

§ If the only prior COVID-19 vaccine dose was a single Novavax COVID-19 vaccine, a 2024-2025 Formula vaccine dose can be given at least 3 to 8 weeks after that dose.

References:
  1. SPIKEVAX (COVID-19 Vaccine, mRNA) Suspension for injection, for intramuscular use; 2024-2025 Formula. US Food and Drug Administration (FDA) approved product information. Revised 4. Available at: https://www.fda.gov/media/155675/download?attachment (Accessed on October 31, 2024).
  2. Fact sheet for healthcare providers administering vaccine: Emergency use authorization of Moderna COVID-19 vaccine (2024-2025 formula), for individuals 6 months through 11 years of age. Available at: https://www.fda.gov/media/167208/download?attachment (Accessed on October 31, 2024).
  3. COMIRNATY (COVID-19 Vaccine, mRNA) suspension for injection, for intramuscular use; 2024-2025 Formula. US Food and Drug Administration (FDA) approved product information. Revised August 22, 2024. Available at: https://www.fda.gov/media/151707/download?attachment (Accessed on October 31, 2024).
  4. Fact sheet for healthcare providers administering vaccine: Emergency use authorization of Pfizer-Biontech COVID-19 vaccine (2024-2025 formula), for 6 months through 11 years of age. Available at: https://www.fda.gov/media/167211/download?attachment (Accessed on October 31, 2024).
  5. Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States. Available at: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html (Accessed on October 31, 2024).
  6. US Food and Drug Administration. Emergency use authorization (EUA) of the Novavax COVID-19 vaccine, adjuvanted (2023-2024 formula), for individuals 12 years or older. Available at: https://www.fda.gov/media/159897/download (Accessed on October 31, 2024).
Graphic 130711 Version 53.0